Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
相关临床试验
0
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
1999
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Sonoma Pharmaceuticals launched its hypochlorous acid-based diaper rash product in 3,600 Walmart stores and Amazon, marking the company's first major US consumer retail expansion. - The company partnered with Medline Industries to launch a new HOCl wound cleanser for US hospitals, combining Sonoma's stabilized hypochlorous acid technology with Medline's extensive healthcare distribution network. - These launches represent significant milestones in Sonoma's US market expansion strategy, bringing clinically proven HOCl products to both consumer and professional healthcare settings. - The products are based on Sonoma's patented Microcyn technology, which has been clinically proven to reduce itch, pain, scarring, and irritation safely without damaging healthy tissue.
- Sonoma Pharmaceuticals has secured MHRA registration for its hypochlorous acid-based acne products, which will be distributed through 1,200+ stores of a leading UK pharmacy chain. - The product line features an acne toner and balancing serum utilizing Sonoma's patented Microcyn technology, offering a gentler alternative to traditional acne treatments containing alcohol or benzoyl peroxide. - This UK market entry represents a strategic expansion of Sonoma's European distribution network, leveraging their clinically proven HOCl formulations that reduce irritation without damaging healthy tissue.
- Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microcyn-based hydrogel, enhancing its wound care applications. - The new clearance includes improved biocompatibility and extends the product's shelf life to 24 months for 50mL bottles. - Microcyn Hydrogel is approved for managing wounds, burns, diabetic ulcers in professional settings, and minor skin irritations over-the-counter. - This regulatory milestone positions Sonoma in the $8.6 billion global wound care market, expanding its reach to both institutional and retail sectors.
